| 1 |
Bekele B, Masresha Z, Alemayehu M, Seyoum B, Wassie L, Abebe M. Intravenous Immunoglobulin G (IVIG) Need Assessment Survey Toward Local Manufacturing of IVIG Using a Mini-Pool Plasma Fractionation Technique. Health Serv Insights 2023;16:11786329231157467. [PMID: 36860668 DOI: 10.1177/11786329231157467] [Reference Citation Analysis]
|
| 2 |
Tocut M, Kolitz T, Shovman O, Haviv Y, Boaz M, Laviel S, Debi S, Nama M, Akria A, Shoenfeld Y, Soroksky A, Zandman-Goddard G. Outcomes of ICU patients treated with intravenous immunoglobulin for sepsis or autoimmune diseases. Autoimmun Rev 2022;21:103205. [PMID: 36195246 DOI: 10.1016/j.autrev.2022.103205] [Reference Citation Analysis]
|
| 3 |
Ojueromi OO, Oboh G, Ademosun AO. Effect of black seeds (Nigella sativa) on inflammatory and immunomodulatory markers in Plasmodium berghei-infected mice. J Food Biochem 2022;46:e14300. [PMID: 35833536 DOI: 10.1111/jfbc.14300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Brun S, de Sèze J, Muller S. CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention. Immuno 2022;2:118-31. [DOI: 10.3390/immuno2010009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Lu CH, Li KJ, Wu CH, Shen CY, Kuo YM, Hsieh SC, Yu CL. The FcγRIII Engagement Augments PMA-Stimulated Neutrophil Extracellular Traps (NETs) Formation by Granulocytes Partially via Cross-Talk between Syk-ERK-NF-κB and PKC-ROS Signaling Pathways. Biomedicines 2021;9:1127. [PMID: 34572313 DOI: 10.3390/biomedicines9091127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Bongomin F, Asio LG, Ssebambulidde K, Baluku JB. Adjunctive intravenous immunoglobulins (IVIg) for moderate-severe COVID-19: emerging therapeutic roles. Curr Med Res Opin 2021;37:903-5. [PMID: 33722106 DOI: 10.1080/03007995.2021.1903849] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 7 |
Adigbli D, Rozen V, Darbar A, Janin P. Early intravenous immunoglobulin therapy for group A β-haemolytic streptococcal meningitis with toxic shock syndrome. BMJ Case Rep 2021;14. [PMID: 33664027 DOI: 10.1136/bcr-2020-238472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 8 |
Cao W, Liu X, Hong K, Ma Z, Zhang Y, Lin L, Han Y, Xiong Y, Liu Z, Ruan L, Li T. High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China. Front Immunol 2021;12:627844. [PMID: 33679771 DOI: 10.3389/fimmu.2021.627844] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 9 |
McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, Muscal E, Lotze T, Srivaths P, Forbes LR, Allen C, Bernhardt MB. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. JAMA Netw Open 2021;4:e2036321. [PMID: 33533931 DOI: 10.1001/jamanetworkopen.2020.36321] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 10 |
Perricone C, Triggianese P, Bursi R, Cafaro G, Bartoloni E, Chimenti MS, Gerli R, Perricone R. Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections. Microorganisms 2021;9:121. [PMID: 33430200 DOI: 10.3390/microorganisms9010121] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 11 |
Fallet B, Walker UA. Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies. Expert Rev Clin Pharmacol 2020;13:1203-18. [PMID: 33008265 DOI: 10.1080/17512433.2020.1832466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 12 |
Liu X, Cao W, Li T. High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects. Front Immunol 2020;11:1660. [PMID: 32760407 DOI: 10.3389/fimmu.2020.01660] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 13 |
Patel V, Cowan J. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency. Expert Rev Clin Immunol 2020;16:711-6. [PMID: 32588670 DOI: 10.1080/1744666X.2020.1788939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 14 |
Reddy A, Muhammad F, J. Lee D. Biological Therapies that Target Inflammatory Cytokines to Treat Uveitis. Advances in the Diagnosis and Management of Uveitis 2019. [DOI: 10.5772/intechopen.82252] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 15 |
Fioravanti A, Tenti S. Intravenous Immunoglobulin Treatment in Rheumatic Diseases. Mosaic of Autoimmunity 2019. [DOI: 10.1016/b978-0-12-814307-0.00061-x] [Reference Citation Analysis]
|
| 16 |
Gomes JP, Santos L, Shoenfeld Y. Intravenous immunoglobulin (IVIG) in the vanguard therapy of Systemic Sclerosis. Clin Immunol 2019;199:25-8. [PMID: 30543921 DOI: 10.1016/j.clim.2018.12.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 17 |
Prezzo A, Cavaliere FM, Milito C, Bilotta C, Iacobini M, Quinti I. Intravenous immunoglobulin replacement treatment reduces in vivo elastase secretion in patients with common variable immune disorders. Blood Transfus 2019;17:103-11. [PMID: 30036181 DOI: 10.2450/2018.0043-18] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 18 |
Tenti S, Fabbroni M, Mancini V, Russo F, Galeazzi M, Fioravanti A. Intravenous Immunoglobulins as a new opportunity to treat discoid lupus erythematosus: A case report and review of the literature. Autoimmun Rev 2018;17:791-5. [PMID: 29885539 DOI: 10.1016/j.autrev.2018.02.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 19 |
Ahn H, Tay J, Shea B, Hutton B, Shorr R, Knoll GA, Cameron DW, Cowan J. Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transfusion 2018;58:2437-52. [PMID: 29770447 DOI: 10.1111/trf.14656] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 20 |
Ramalho CC, Neves CMSS, Quental MV, Coutinho JAP, Freire MG. Separation of immunoglobulin G using aqueous biphasic systems composed of cholinium-based ionic liquids and poly(propylene glycol). J Chem Technol Biotechnol 2018;93:1931-9. [PMID: 30270961 DOI: 10.1002/jctb.5594] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 21 |
Shemer A, Kivity S, Shoenfeld Y. Clinical indications for intravenous immunoglobulin utilization in a tertiary medical center: a 9-year retrospective study. Transfusion 2018;58:430-8. [PMID: 29193136 DOI: 10.1111/trf.14427] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 22 |
Sordé L, Spindeldreher S, Palmer E, Karle A. Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action? PLoS One 2017;12:e0186046. [PMID: 29023507 DOI: 10.1371/journal.pone.0186046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 23 |
Ravindranath MH. HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs. J Immunol Res 2017;2017:3475926. [PMID: 28634589 DOI: 10.1155/2017/3475926] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 24 |
Sanges S, Rivière S, Mekinian A, Martin T, Le Quellec A, Chatelus E, Lescoat A, Jego P, Cazalets C, Quéméneur T, Le Gouellec N, Senet P, Francès C, Deroux A, Imbert B, Fain O, Boukari L, Sené T, Deligny C, Mathian A, Agard C, Pugnet G, Speca S, Dubucquoi S, Hatron PY, Hachulla É, Launay D. Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature. Autoimmun Rev 2017;16:377-84. [PMID: 28232167 DOI: 10.1016/j.autrev.2017.02.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 25 |
Hollis C, Pennant M, Cuenca J, Glazebrook C, Kendall T, Whittington C, Stockton S, Larsson L, Bunton P, Dobson S, Groom M, Hedderly T, Heyman I, Jackson GM, Jackson S, Murphy T, Rickards H, Robertson M, Stern J. Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis. Health Technol Assess. 2016;20:1-450, vii-viii. [PMID: 26786936 DOI: 10.3310/hta20040] [Cited by in Crossref: 72] [Cited by in F6Publishing: 92] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 26 |
Ammann EM, Haskins CB, Fillman KM, Ritter RL, Gu X, Winiecki SK, Carnahan RM, Torner JC, Fireman BH, Jones MP, Chrischilles EA. Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of RCTs. Am J Hematol 2016;91:594-605. [PMID: 26973084 DOI: 10.1002/ajh.24358] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 27 |
Prezzo A, Cavaliere FM, Bilotta C, Iacobini M, Quinti I. Intravenous immunoglobulin replacement treatment does not alter polymorphonuclear leukocytes function and surface receptors expression in patients with common variable immunodeficiency. Cell Immunol 2016;306-307:25-34. [PMID: 27264689 DOI: 10.1016/j.cellimm.2016.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 28 |
Svetlicky N, Kivity S, Odeh Q, Shovman O, Gertel S, Amital H, Gendelman O, Volkov A, Barshack I, Bar-Meir E, Blank M, Shoenfeld Y. Anti-citrullinated-protein-antibody-specific intravenous immunoglobulin attenuates collagen-induced arthritis in mice. Clin Exp Immunol 2015;182:241-50. [PMID: 26132809 DOI: 10.1111/cei.12673] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 29 |
Cowan J, Cameron DW, Knoll G, Tay J. Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantation. BMJ Open 2015;5:e008316. [PMID: 26297369 DOI: 10.1136/bmjopen-2015-008316] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 30 |
Katz-Agranov N, Khattri S, Zandman-Goddard G. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. Autoimmun Rev 2015;14:651-8. [PMID: 25870941 DOI: 10.1016/j.autrev.2015.04.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 31 |
Caforio AL, Angelini A, Blank M, Shani A, Kivity S, Goddard G, Doria A, Schiavo A, Testolina M, Bottaro S, Marcolongo R, Thiene G, Iliceto S, Shoenfeld Y. Passive transfer of affinity-purified anti-heart autoantibodies (AHA) from sera of patients with myocarditis induces experimental myocarditis in mice. International Journal of Cardiology 2015;179:166-77. [DOI: 10.1016/j.ijcard.2014.10.165] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 32 |
Tjon AS, van Gent R, Jaadar H, Martin van Hagen P, Mancham S, van der Laan LJ, te Boekhorst PA, Metselaar HJ, Kwekkeboom J. Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production. J Immunol. 2014;192:5625-5634. [PMID: 24808368 DOI: 10.4049/jimmunol.1301260] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 33 |
Trépanier P, Chabot D, Bazin R. Intravenous immunoglobulin modulates the expansion and cytotoxicity of CD8+ T cells. Immunology 2014;141:233-41. [PMID: 24128001 DOI: 10.1111/imm.12189] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 34 |
Sun A, Teschner W, Yel L. Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects. Expert Review of Clinical Immunology 2014;9:577-87. [DOI: 10.1586/eci.13.39] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 35 |
Danieli MG, Moretti R, Gambini S, Paolini L, Gabrielli A. Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis. Clin Rheumatol 2014;33:531-6. [DOI: 10.1007/s10067-013-2478-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 36 |
Wu Y, Champagne J, Toueille M, Gantier R, Burnouf T. Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI/activated FXI from human plasma IgG: Removal of IgA, IgM, and FXI from IgG. Transfusion 2014;54:169-78. [DOI: 10.1111/trf.12243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 37 |
Trépanier P, St-Amour I, Bazin R. Cationized IVIg as a potential substitute to IVIg for the treatment of experimental immune thrombocytopenia. Int Immunopharmacol 2013;16:409-13. [PMID: 23665226 DOI: 10.1016/j.intimp.2013.04.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 38 |
Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013;11:88. [PMID: 23557513 DOI: 10.1186/1741-7015-11-88] [Cited by in Crossref: 157] [Cited by in F6Publishing: 155] [Article Influence: 15.7] [Reference Citation Analysis]
|
| 39 |
Menachem A, Chapman J, Deri Y, Pick CG, Katzav A. Immunoglobulin-Mediated Neuro-Cognitive Impairment: New Data and a Comprehensive Review. Clinic Rev Allerg Immunol 2013;45:248-55. [DOI: 10.1007/s12016-013-8357-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 40 |
Ballow MC. Immunoglobulin therapy. Clinical Immunology 2013. [DOI: 10.1016/b978-0-7234-3691-1.00098-2] [Reference Citation Analysis]
|
| 41 |
Younger ME, Aro L, Blouin W, Duff C, Epland KB, Murphy E, Sedlak D; Nurse Advisory Committee Immune Deficiency Foundation. Nursing guidelines for administration of immunoglobulin replacement therapy. J Infus Nurs 2013;36:58-68. [PMID: 23271153 DOI: 10.1097/NAN.0b013e3182798af8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 42 |
Svetlicky N, Ortega-Hernandez OD, Mouthon L, Guillevin L, Thiesen HJ, Altman A, Kravitz MS, Blank M, Shoenfeld Y. The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade. J Clin Immunol 2013;33 Suppl 1:S27-32. [PMID: 23229779 DOI: 10.1007/s10875-012-9842-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 43 |
Nussinovitch U, Shoenfeld Y. The diagnostic and clinical significance of anti-muscarinic receptor autoantibodies. Clin Rev Allergy Immunol 2012;42:298-308. [PMID: 21207192 DOI: 10.1007/s12016-010-8235-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 44 |
Raithatha AH, Bryden DC. Use of intravenous immunoglobulin therapy in the treatment of septic shock, in particular severe invasive group A streptococcal disease. Indian J Crit Care Med 2012;16:37-40. [PMID: 22557832 DOI: 10.4103/0972-5229.94433] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 45 |
Danieli MG, Pettinari L, Marinangeli L, Logullo F. Recurrent myelitis in common variable immunodeficiency successfully managed with high-dose subcutaneous immunoglobulin. BMJ Case Rep 2012;2012:bcr0120125637. [PMID: 22878981 DOI: 10.1136/bcr-01-2012-5637] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 46 |
Shoenfeld Y. The future of autoimmunity. Clin Rev Allergy Immunol 2012;42:113-20. [PMID: 22203433 DOI: 10.1007/s12016-011-8297-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 47 |
Dior M, Coriat R, Mir O, Brezault C, Perkins G, Dhooge M, Goldwasser F, Chaussade S. A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia. Am J Med 2012;125:828-30. [PMID: 22840668 DOI: 10.1016/j.amjmed.2012.04.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 48 |
Brooks WH. Mechanisms and pathophysiology of autoimmune disease. Clin Rev Allergy Immunol 2012;42:1-4. [PMID: 22187334 DOI: 10.1007/s12016-011-8298-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 49 |
Vargas M, Segura A, Herrera M, Villalta M, Angulo Y, Gutiérrez JM, León G, Burnouf T. Purification of IgG and albumin from human plasma by aqueous two phase system fractionation. Biotechnol Prog 2012;28:1005-11. [PMID: 22619188 DOI: 10.1002/btpr.1565] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 50 |
Solano S, Segura Á, León G, Gutiérrez J, Burnouf T. Low pH formulation of whole IgG antivenom: Impact on quality, safety, neutralizing potency and viral inactivation. Biologicals 2012;40:129-33. [DOI: 10.1016/j.biologicals.2011.11.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 51 |
Gershwin ME, Shoenfeld Y. Cutting-edge issues in organ-specific autoimmunity. Clin Rev Allergy Immunol 2011;41:123-5. [PMID: 21887609 DOI: 10.1007/s12016-011-8283-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 52 |
Altarescu G, Geva TE, Grisaru-granovsky S, Bonstein L, Miskin H, Varshver I, Margalioth EJ, Levy-lahad E, Renbaum P. Preimplantation Genetic Diagnosis for Fetal Neonatal Alloimmune Thrombocytopenia Due to Antihuman Platelet Antigen Maternal Antibodies: . Obstetrics & Gynecology 2012;119:338-43. [DOI: 10.1097/aog.0b013e318242a11d] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 53 |
Rozman Z, Zandman-goddard G. Intravenous immunoglobulin therapy for SLE. Immunotherapeutic Agents for SLE 2012. [DOI: 10.2217/ebo.11.328] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 54 |
Burnouf T. Plasma fractionation in Asia-Pacific: challenges and perspectives. ISBT Science Series 2011;6:366-372. [DOI: 10.1111/j.1751-2824.2011.01517.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 55 |
Nussinovitch U, Shoenfeld Y. The role of gender and organ specific autoimmunity. Autoimmun Rev 2012;11:A377-85. [PMID: 22100310 DOI: 10.1016/j.autrev.2011.11.001] [Cited by in Crossref: 95] [Cited by in F6Publishing: 102] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 56 |
Casulli S, Topçu S, Fattoum L, von Gunten S, Simon HU, Teillaud JL, Bayry J, Kaveri SV, Elbim C. A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms. PLoS One 2011;6:e26469. [PMID: 22065996 DOI: 10.1371/journal.pone.0026469] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 57 |
Zandman-goddard G, Krauthammer A, Levy Y, Langevitz P, Shoenfeld Y. Long-Term Therapy with Intravenous Immunoglobulin is Beneficial in Patients with Autoimmune Diseases. Clinic Rev Allerg Immunol 2012;42:247-55. [DOI: 10.1007/s12016-011-8278-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 58 |
Kayed R, Jackson GR, Estes DM, Barrett AD. Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins. J Cent Nerv Syst Dis 2011;3:67-73. [PMID: 23861639 DOI: 10.4137/JCNSD.S5018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 59 |
Wasserman RL, Irani AM, Tracy J, Tsoukas C, Stark D, Levy R, Chen J, Sorrells S, Roberts R, Gupta S. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol 2010;161:518-26. [PMID: 20550549 DOI: 10.1111/j.1365-2249.2010.04195.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 60 |
Farrugia A, Penrod J, Bult JM. Payment, compensation and replacement--the ethics and motivation of blood and plasma donation. Vox Sang 2010;99:202-11. [PMID: 20576023 DOI: 10.1111/j.1423-0410.2010.01360.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 61 |
Nussinovitch U, Shoenfeld Y. The Clinical Significance of Anti-Beta-1 Adrenergic Receptor Autoantibodies in Cardiac Disease. Clinic Rev Allerg Immunol 2013;44:75-83. [DOI: 10.1007/s12016-010-8228-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 62 |
Burnouf T. Recombinant plasma proteins: Recombinant plasma proteins. Vox Sanguinis 2011;100:68-83. [DOI: 10.1111/j.1423-0410.2010.01384.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 63 |
Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Sibéril S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Lévy Y, Mouthon L, Sautès-Fridman C, Hermine O, Kaveri SV. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun 2011;36:9-15. [PMID: 20970960 DOI: 10.1016/j.jaut.2010.09.006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 64 |
Du W, Klibanov AM. Hydrophobic salts markedly diminish viscosity of concentrated protein solutions. Biotechnol Bioeng 2011;108:632-6. [PMID: 21246510 DOI: 10.1002/bit.22983] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 65 |
Israeli E, Agmon-levin N, Blank M, Chapman J, Shoenfeld Y. Guillain–Barré Syndrome—A Classical Autoimmune Disease Triggered by Infection or Vaccination. Clinic Rev Allerg Immunol 2012;42:121-30. [DOI: 10.1007/s12016-010-8213-3] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 66 |
Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 2011;10:144-9. [PMID: 20858553 DOI: 10.1016/j.autrev.2010.09.004] [Cited by in Crossref: 95] [Cited by in F6Publishing: 82] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 67 |
Galeotti C, Bayry J, Kone-Paut I, Kaveri SV. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev 2010;9:441-8. [PMID: 20004744 DOI: 10.1016/j.autrev.2009.12.004] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 5.7] [Reference Citation Analysis]
|
